Absolute Lymphocyte Count (ALC) Calculator — Lymphopenia Grading & Differential

How to Use This Calculator

1. Enter WBC count (×10³/μL) and lymphocyte % from the CBC differential.
2. ALC, NCI CTCAE grade, and clinical interpretation display instantly.
3. Use the Severity tab for context-specific guidance (chemo, COVID, HIV).
4. Use the Elevated ALC tab for lymphocytosis differential diagnosis.

Formula

Example

Frequently Asked Questions

• What is the Absolute Lymphocyte Count (ALC)? ▼
  The Absolute Lymphocyte Count (ALC) is the total number of lymphocytes — the white blood cells responsible for adaptive immunity, including T cells, B cells, and natural killer (NK) cells — in one microlitre of blood. It is calculated by multiplying the total WBC count (×10³/μL) by the lymphocyte percentage from the differential, then multiplying by 1,000: ALC = WBC × lymphocyte% × 10 = cells/μL. The normal ALC range in adults is approximately 1,000–4,800 cells/μL, with a commonly used lower limit of 1,500 cells/μL. ALC reflects the functional status of the adaptive immune system. It is routinely reported as part of a complete blood count (CBC) with differential and requires no additional laboratory testing. ALC is clinically important in oncology (monitoring immunosuppressive effects of chemotherapy and immunotherapy), infectious disease (HIV/AIDS staging, viral illness assessment), autoimmune disease management, and critical care. Unlike the ANC, which primarily reflects bacterial and fungal defence, ALC reflects the capacity for specific immune responses against viruses, intracellular organisms, and malignant cells.
• What does a low ALC (lymphopenia) mean? ▼
  Lymphopenia is defined as ALC below 1,500 cells/μL in adults, though the clinically significant threshold for immune dysfunction is generally considered ALC below 1,000 cells/μL. NCI CTCAE grading: Grade 1 (mild) = 800–1,499 cells/μL; Grade 2 (moderate) = 500–799 cells/μL; Grade 3 (severe) = 200–499 cells/μL; Grade 4 (life-threatening) = below 200 cells/μL. Clinically, the major concern with lymphopenia is susceptibility to opportunistic infections — particularly viral infections (herpes zoster, CMV, EBV reactivation), fungal infections (Pneumocystis jirovecii pneumonia, cryptococcosis), and mycobacterial infections. The most common causes in hospitalised patients are: chemotherapy and radiation therapy (direct lymphocyte destruction); corticosteroid administration (lymphocyte redistribution and apoptosis); viral infections including COVID-19 and HIV; malnutrition and chronic illness; and autoimmune diseases such as systemic lupus erythematosus. Severe persistent lymphopenia (Grade 3-4) warrants investigation for underlying primary immunodeficiency, haematological malignancy, or opportunistic infection, and typically mandates antimicrobial prophylaxis.
• How does ALC relate to CD4 count in HIV? ▼
  In HIV-positive patients, ALC can serve as a rough proxy for the CD4+ T-cell count when flow cytometry is unavailable, though it is a crude approximation. The relationship is based on the fact that CD4+ T cells constitute approximately 25–35% of total lymphocytes in healthy individuals; in HIV-infected patients, this fraction is reduced, but ALC still tracks broadly with CD4 count. Empirical correlations suggest: ALC approximately 2,000 cells/μL correlates roughly with CD4 approximately 700 cells/μL; ALC approximately 1,500 correlates with CD4 approximately 500; ALC approximately 800 correlates with CD4 approximately 200; ALC approximately 500 correlates with CD4 approximately 100. These thresholds are clinically significant because CD4 200 cells/μL marks the threshold for mandatory Pneumocystis jirovecii pneumonia (PCP) prophylaxis, and CD4 100 triggers Toxoplasma and MAC prophylaxis. In resource-limited settings where CD4 flow cytometry is not available, ALC has been used to guide antiretroviral therapy initiation and opportunistic infection prophylaxis decisions. However, ALC should never replace direct CD4 measurement when available, as the variability in individual correlation is too high for treatment decisions.
• Why is ALC monitored during chemotherapy? ▼
  Monitoring ALC during chemotherapy is important for several reasons that go beyond the more familiar ANC monitoring. Many chemotherapy agents — particularly alkylating agents (cyclophosphamide, melphalan), purine analogues (fludarabine, cladribine), and taxanes — are profoundly lymphotoxic, causing severe lymphopenia that can persist for months after treatment completion. Severe lymphopenia (ALC below 200 cells/μL) during chemotherapy confers significant risk of opportunistic infections, particularly Pneumocystis jirovecii pneumonia, herpes zoster, and CMV reactivation. Most institutional guidelines recommend trimethoprim-sulfamethoxazole (cotrimoxazole) PCP prophylaxis when ALC falls below 200 cells/μL or in patients receiving corticosteroid-containing regimens. For immunotherapy (checkpoint inhibitors), baseline and on-treatment ALC has emerging prognostic value: several studies have shown that higher baseline ALC correlates with improved objective response rates and overall survival in patients receiving anti-PD-1/PD-L1 therapy, reflecting the importance of intact T-cell immunity for immunotherapy efficacy. Serial ALC monitoring also helps identify severe immune-related adverse events (Grade 3-4 lymphopenia) that may require treatment modification.
• What causes an elevated ALC (lymphocytosis)? ▼
  Lymphocytosis is defined as ALC above 4,000–4,500 cells/μL in adults. It is classified as reactive (benign) or malignant. Reactive lymphocytosis is the most common cause and occurs in response to viral infections. Infectious mononucleosis (Epstein-Barr virus) causes characteristic atypical lymphocytosis with ALC typically 5,000–20,000 cells/μL. Other viral causes include CMV, HIV seroconversion, hepatitis, adenovirus, and rubella. Pertussis (whooping cough) causes marked lymphocytosis up to 30,000–50,000 cells/μL from a distinct T-cell-stimulating mechanism. Stress lymphocytosis occurs transiently after physical or psychological stress, resolving within hours. Malignant lymphocytosis raises immediate concern for chronic lymphocytic leukaemia (CLL), the most common adult leukaemia in Western countries — typically presenting with ALC above 10,000 cells/μL with a monomorphic mature lymphocyte morphology on peripheral smear. Other malignant causes include large granular lymphocyte leukaemia, mantle cell lymphoma with leukaemic phase, and acute lymphoblastic leukaemia (ALL). In any adult with persistently elevated ALC above 5,000 cells/μL beyond the resolution of an acute illness, peripheral blood flow cytometry is indicated to distinguish reactive from clonal lymphocytosis and characterise the lymphocyte phenotype.

Related Calculators